Greenwich LifeSciences, Inc.
GLSI
$22.23
$0.582.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 518.20K | 355.20K | 653.10K | 538.00K | 497.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.73M | 7.95M | 4.17M | 4.05M | 2.77M |
| Operating Income | -5.73M | -7.95M | -4.17M | -4.05M | -2.77M |
| Income Before Tax | -5.66M | -7.92M | -4.15M | -4.03M | -2.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.66M | -7.92M | -4.15M | -4.03M | -2.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.66M | -7.92M | -4.15M | -4.03M | -2.74M |
| EBIT | -5.73M | -7.95M | -4.17M | -4.05M | -2.77M |
| EBITDA | -5.73M | -7.95M | -4.17M | -4.05M | -2.77M |
| EPS Basic | -0.39 | -0.57 | -0.30 | -0.30 | -0.21 |
| Normalized Basic EPS | -0.24 | -0.35 | -0.19 | -0.19 | -0.13 |
| EPS Diluted | -0.39 | -0.57 | -0.30 | -0.30 | -0.21 |
| Normalized Diluted EPS | -0.24 | -0.35 | -0.19 | -0.19 | -0.13 |
| Average Basic Shares Outstanding | 14.57M | 13.95M | 13.64M | 13.37M | 13.17M |
| Average Diluted Shares Outstanding | 14.57M | 13.95M | 13.64M | 13.37M | 13.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |